02:15 PM EST - Mindset Pharma Inc. : Today provided a recap of its 2021 milestones and highlights. “In 2021, we made significant progress in building our portfolio of next-generation psychedelic compounds showing improved preclinical safety and efficacy of 5-MeO-DMT and psilocybin-based therapies,” said James Lanthier, CEO of Mindset. Operational Highlights include an Expanded Patent Portfolio, an Advanced First Lead Drug Candidate Toward Clinical Trials, Effect Size & Safety Differentiation Driven by Technology Platform. Mindset Pharma Inc.
shares C.MSET are trading up 0.03 cents at $0.85.
